BioMarin Pharmaceutical Inc. (LON:0HNC)
London flag London · Delayed Price · Currency is GBP · Price in USD
58.01
-1.15 (-1.94%)
At close: Jul 11, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
NAGLAZYME
479.58M
Log In
Log In
Log In
Log In
Upgrade
NAGLAZYME Growth
21.18%
Log In
Log In
Log In
Log In
Upgrade
ALDURAZYME
183.89M
Log In
Log In
Log In
Log In
Upgrade
ALDURAZYME Growth
49.58%
Log In
Log In
Log In
Log In
Upgrade
KUVAN
120.90M
Log In
Log In
Log In
Log In
Upgrade
KUVAN Growth
-33.74%
Log In
Log In
Log In
Log In
Upgrade
FIRDAPSE
-
Log In
Log In
Log In
Log In
Upgrade
FIRDAPSE Growth
-
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other
44.47M
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other Growth
-7.89%
Log In
Log In
Log In
Log In
Upgrade
VIMIZIM
739.78M
Log In
Log In
Log In
Log In
Upgrade
VIMIZIM Growth
4.43%
Log In
Log In
Log In
Log In
Upgrade
BRINEURA
169.08M
Log In
Log In
Log In
Log In
Upgrade
BRINEURA Growth
5.32%
Log In
Log In
Log In
Log In
Upgrade
PALYNZIQ
355.05M
Log In
Log In
Log In
Log In
Upgrade
PALYNZIQ Growth
17.44%
Log In
Log In
Log In
Log In
Upgrade
VOXZOGO
735.09M
Log In
Log In
Log In
Log In
Upgrade
VOXZOGO Growth
48.80%
Log In
Log In
Log In
Log In
Upgrade
ROCTAVIAN
26.07M
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other
44.47M
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other Growth
-7.89%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Royalty and Other
44.47M
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other Growth
-7.89%
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other
44.47M
Log In
Log In
Log In
Log In
Upgrade
Royalty and Other Growth
-7.89%
Log In
Log In
Log In
Log In
Upgrade
United States
924.81M
Log In
Log In
Log In
Log In
Upgrade
United States Growth
22.07%
Log In
Log In
Log In
Log In
Upgrade
Europe
829.03M
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
22.50%
Log In
Log In
Log In
Log In
Upgrade
Latin America
378.08M
Log In
Log In
Log In
Log In
Upgrade
Latin America Growth
12.96%
Log In
Log In
Log In
Log In
Upgrade
Rest of World Revenue (Pre-Q3 2024)
-
Log In
Log In
Log In
Log In
Upgrade
Rest of World Revenue (Pre-Q3 2024) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
677.52M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
57.70%
Log In
Log In
Log In
Log In
Upgrade